Inovio Pharmaceuticals(US:INO)2023-11-10 04:11VGX-3100 for Anal HSIL - In a Phase 2 open-label trial, VGX-3100 showed a 50% clearance rate of HPV-16/18+ lesions in HIV-negative participants with anal HSIL at Week 36[1], compared to an estimated spontaneous rate of less than 27%[1] - 46% of participants showed no evidence of HPV-16/18 virus at Week 36[1] - INOVIO is considering Phase 3 trial designs for VGX-3100 aligned with the evolving treatment paradigm for Anal HSIL[5] INO-3112 for HPV-Related Cancer - In a Phase 1b/2a trial, the overall response rate (ORR) for INO-3112 in combination with durvalumab in HPV-positive head and neck squamous cell carcinoma (HNSCC) participants was 27.6% (4 CR, 4 PR) in 29 evaluable patients[8] - Treatment with INO-3112 resulted in infiltration of CD8+ immune cells into head and neck tumors[8, 23] INO-5401 for Glioblastoma - In a Phase 1/2 trial, INO-5401 + INO-9012 combined with Libtayo® showed a median overall survival (OS) of 17.9 months in unmethylated newly diagnosed glioblastoma (GBM) patients, compared to a historical 14.6-16 months[15] - Methylated newly diagnosed GBM patients treated with INO-5401 + INO-9012 combined with Libtayo® showed a median OS of 32.5 months, compared to a historical 23.2-25 months[15] INO-4201 for Ebola - In a Phase 1b trial, INO-4201, as a booster in participants previously vaccinated with Ervebo®, boosted humoral responses in 100% (36 of 36) of treated participants[21] Financial Status - INOVIO had $194.9 million in cash, cash equivalents, and short-term investments as of June 30, 2023[30]